Ablynx completes funding, raises €50 million
This article was originally published in Scrip
Belgian antibody firm Ablynx has completed its secondary public offering, raising €50 million through the sale of just under 6.7 million new shares at €7.50 each. An over-allotment option of up to 400,000 shares worth €3 million in total will be covered by lending shareholders selling existing shares. The company said that the base offering at the final offer price was subscribed by about 1.1 times. The transaction leaves Ablynx with a market capitalisation of around €327 million based on the final offer price. The new shares are expected to begin trading on Euronext Brussels on March 18th. Ablynx announced its offering last week, when it set the offer price range at €7.20-7.75 (scripnews.com, March 8th, 2010).
You may also be interested in...
Previewing the year to come, our journalists contacted more than 80 industry executives and experts for their views on what 2020 could hold for the biopharma sector. A series of articles based on these discussions were published by In Vivo’s sister publication Scrip. The following are highlights of the key issues that are top of mind for industry leaders this year, including digital tools, advanced therapies, the US election and manufacturing.
From the general to the particular: drug developers are increasingly tailoring therapies to individuals. Driven by important advances in understanding biology as well as new tools to harness big data, industry participants expect significant progress in biopharma’s approach to the patient.
The US election will intensify the spotlight on drug costs, regulators will have their hands full with advanced therapy filings, and the need to address rising infectious disease threats will mount. Biosimilars, cannabis and Brexit are among other hot topics for 2020.